


**Claims**

1. A compound of the formula (I):



(I)

wherein:

R¹ is hydrogen, halo or methoxy;

R² is hydrogen, halo, methyl, ethyl or methoxy;

R³ is carboxy, tetrazolyl or -CONHSO₂R⁴ where R⁴ is methyl, ethyl, phenyl, 2,5-dimethylisoxazolyl or trifluoromethyl;

T is -CH₂- or -SO₂-; and

ring A is 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl;

or a pharmaceutically acceptable salt or prodrug thereof.

2. A compound according to claim 1 wherein ring A is 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl or 3-chloro-4-fluorophenyl.

20

3. A compound according to claim 2 wherein ring A is 3,4-dichlorophenyl, 3-fluoro-4-chlorophenyl or 3-chloro-4-fluorophenyl.

25

4. A compound according to claim 1 wherein ring A is 3,4-dichlorophenyl, 2,3-dichloropyrid-5-yl or 3-chloro-4-fluorophenyl.

*Selby* 5. A compound according to any one of the preceding claims wherein T is -CH<sub>2</sub>-.

*B1* 6. A compound according to any one of the preceding claims where R<sup>3</sup> is carboxy.

5

7. A compound according to claim 1 wherein in the compound of formula (I),

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is hydrogen;

R<sup>3</sup> is carboxy;

10

T is -CH<sub>2</sub>-; and


ring A is 3,4-dichlorophenyl or 3-chloro-4-fluorophenyl;

or a pharmaceutically acceptable salt or prodrug thereof.

15

8. A process for preparing a compound according to claim 1 which process comprises:


a) reacting compounds of formula (II):



(II)

where R<sup>a</sup> is a group R<sup>3</sup> as defined in claim 1 or protected form of a group R<sup>3</sup>, R<sup>b</sup> is

20 hydrogen or a hydroxy protecting group, and R<sup>1</sup> and R<sup>2</sup> are as defined in claim 1, with a compound of formula (III):



(III)

where T and ring A are as defined in claim 1, and L is a displaceable group;

25 and thereafter if necessary:

- i) converting a compound of the formula (I) into another compound of the formula (I);
- ii) removing any protecting groups; or
- iii) forming a pharmaceutically acceptable salt or prodrug thereof.

5 9. A pharmaceutical composition comprising a compound according to any one of claims 1 to 7 in combination with a pharmaceutically acceptable carrier.

10. 10. A compound according to any one of claims 1 to 7 for use in the preparation of a medicament for use in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.

TOP SECRET - SECURITY INFORMATION

